RxDoctor Payments Data

Arnold-Peter Weiss, MD

Hand Surgery · Providence, RINPI 1164470597

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $492,520 of the $568,422 with a category attached, or 86.6%. Anika Therapeutics, Inc. accounts for 64.9% of it on its own, with 3 other manufacturers making up the rest.

$568,422in general payments, 2019–2025

Across 104 payments — averaging $5465.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Anika Therapeutics, Inc.$369K
  • Arthrosurface Incorporated$123K
  • Medartis Inc.$77K
  • Axogen$119
$44,500in research payments, 2019–2025

Across 2 payments — averaging $22,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sonex Health, Inc.$45K

What the payments were for

  • Royalty or licence$492,52087%
  • Consulting fees$50,1259%
  • Speaking & faculty fees$12,1002%
  • Travel & lodging$12,7912%
  • Food & beverage$8860%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Anika Therapeutics, Inc.70$369,049
Arthrosurface Incorporated24$122,598
Medartis Inc.9$76,656
Axogen1$119

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hand surgery providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$111,539
Medicare patients
254
Services billed
727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam142$471

Paid to pharmacies, not to this prescriber.

Other hand surgery in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →